Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | FLT3 exon 14 ins |
Therapy | Decitabine + Quizartinib + Venetoclax |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 exon 14 ins | acute myeloid leukemia | predicted - sensitive | Decitabine + Quizartinib + Venetoclax | Phase Ib/II | Actionable | In a Phase I/II trial, treatment with the combination of Vanflyta (quizartinib), Venclexta (venetoclax), and Dacogen (decitabine) resulted in a composite complete remission (CRc) rate of 68% (27/40), a median overall survival (OS) of 7.1 months, and a 1-year OS rate of 22% in relapsed/refractory acute myeloid leukemia patients with FLT3-ITD mutations, and in the frontline setting, the combination treatment resulted in a CRc of 100% (10/10) (Blood (2023) 142 (Supplement 1): 158; NCT03661307). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML | Full reference... |